Anavex Life Sciences Corp (AVXL)

[Steady_T]

Yes I did feel the need to point out the assumption you made in your post.
Of course there is a possibility that there will be questions that arise at the scheduled clock stops, just as there is a possibility that there will be none.
How big an impact those questions will have, if any, on the total timeline is an unknown.

I doubt that many MAAs will go straight through without ever touching the walls within the CHMP offices.[/quote

Actually the average length of time for the EMA review process of New Active Substances averaged 436 days in 2018.
With the Accelerated Assessment option the average was 230 days.